Guru P. Sonpavde, MD✓

New #bladdercancer #clinicaltrial opening now: Bladder-preservation for muscle-invasive #bladdercancer (MIBC) - #TroFuse055 is a Phase III clinical trial that evaluates the value of neoadjuvant sacituzumab tirumotecan (Sac-TMT) + MK3475A followed by consolidation MK3475A when combined with conventional chemoradiotherapy - this trial builds upon the value that chemoradiation brings to patients with MIBC who have elected to avoid radical cystectomy surgery - 1) Sac-TMT is a Trop2 binding antibody drug conjugate (ADC) conjugated to a potent topoisomerase-1 inhibitor payload (belotecan) and 2) MK3475A is subcutaneous pembrolizumab - Trial is opening globally and sponsored by @Merck - we are pleased to offer at our institution @AdventHealthCFL Cancer Institute Orlando, #Florida - Please note @BladderCancerUS @FLASCO_ORG @tompowles1 @DrYukselUrun @drenriquegrande @AndreaNecchi @shilpaonc -

#clinicaltrial commentary - is a Phase 1 trial for #cancer therapy a good option? My opinion from @AdventHealthCFL - please note @VivekSubbiah @BladderCancerUS @FLASCO_ORG @VuMedi @OncoAlert @OncBrothers @oncodaily

RT @Onco_Nexus: What does a biomarker driven approach look like in MIBC? In this clip, @UroDocAsh shares his insights on newer strategies like utDNA surveillance and its need to prove clear value alongside established tools like FISH and ctDNA. Full Discussion: @siadaneshmand @MattGalsky @sonpavde @BradMcG04 @PGrivasMDPhD

We are #Hiring at @AdventHealthCFL #cancer Institute, Orlando, #Florida area! Looking for Genitourinary (GU) #cancer-focused medical Hematologist-Oncologist to also support the rapidly growing Phase I solid tumor #clinicaltrial program- especially suitable for a junior medical oncologist who is interested in a hybrid of #prostatecancer focused medical oncology practice + clinical trials (#research) and wants to develop an #earlydrugdevelopment career- and an opportunity to collaborate with world class urology and Radiation Oncology team - flexibly tailor the practice to fit career goals - @AdventHealthCFL was ranked as one of the top 20 hospitals by US News & World Report in 2025-and the among the top 50 in the nation for 6 medical specialties including #Cancer - we are the largest healthcare system in central Florida - and a teaching program with Internal Medicine residency - and will have a Hematology-Oncology fellowship in the near future

Please note @HemOncFellows

RT @OncLive: Moving the needle in MIBC: From novel neoadjuvant therapies to Signatera assay integration. Dive into our latest 12-episode series featuring top oncology experts as they discuss personalizing treatment and improving patient communication through ctDNA. Stream here: @tompowles1 @QMBCI @alantanmd @VUmedicine @sonpavde @AdventHealthCFL @PGrivasMDPhD @fredhutch @OncoBellmunt @DanaFarber_GU

#PenileCancer update at #MaTOSGU2026 - Pleased to attend and discuss from @Adventhealth #Cancer Institute @AdventHealthCFL, Orlando, #Florida - Global collaboration is critically important to accelerate advances #GSRGT (Global Society of Rare GU Tumors) @AndreaNecchi @SpiessPhilippe @JadChahoud @apolo_andrea - thanks to organizers @PGrivasMDPhD @LuisERaez1 @mecmededucation

RT @siadaneshmand: Really enjoyed this session with colleagues ⁦@UroDocAsh⁩ @BradMcG04 @mattgalsky ⁦@sonpavde led by ⁦@PGrivasMDPhD⁩ What’s Next in Bladder Cancer Treatment? -

RT @arnabguonc: Enjoyed debating #Joshlinscott of @MoffittNews on bladder sparing after CCR - not primetime yet but #utDNA and #ctDNA will be 🔑! Studies Coming soon! @sonpavde @shilpaonc @koshkin85 @alantanmd @OncoAlert @ZakhariaYousef @Parminder1699 @tompowles1

RT @OLNGreatDebates: The debates are concluded but the conversations are still going! Thanks to the faculty and clinicians who made OLN Great Debates in Solid Tumors in Miami a thoughtful, practical exchange on real decision points in solid tumor care. New York is next! Sept 26–27 #OLNGreatDebates #Oncology @Latinamd @KelseyPanMD @arnabguonc @sonpavde

RT @siadaneshmand: It was a pleasure to discuss the latest findings that bring new treatments to our patients #GU26. Honor to be among these amazing leaders led by the charismatic and visionary leader @PGrivasMDPhD along with @UroDocAsh, @oncologydoc @sonpavde, Brad McGregor MD. #bladdercancer #clinicaltrials @BladderCancerUS @IBCG_BladderCA @ASCO @ASCOPost

Live from ASCO GU: Key leaders in bladder cancer are diving into the data shaping practice today. @PGrivasMDPhD @UroDocAsh @sonpavde @siadaneshmand @MattGalsky @BradMcG04

Pleased to have mentored @rohitjainMD on this #clinicaltrial combining EV plus pan -FGFR inhibiting targeted agent Erdafitinib for advanced #bladdercancer #urothelialcarcinoma

RT @FaltasLab: Congratulations to my colleague @rohitjainMD on this important IIT of FGFR3i + EV in metastatic urothelial cancer #BladderCancer #GU26 @WCMGUcancer

#GU26 Proud to share #ETCTN10483 (IIT): Phase Ib erdafitinib + enfortumab vedotin in FGFR2/3-altered mUC (n=15) post chemo + IO. ORR 93%, median PFS 11.7 mo, OS 23.2 mo. Strong signal of biologic synergy. #BladderCancer #FGFR #ETCTN